Recent breakthrough studies on the pharmacological effects of sodium glucose cotransporter 2 (SGLT2) inhibitors, originally developed as diabetes medications, have highlighted their efficacy in treating not only diabetes mellitus but also heart failure and chronic kidney disease (CKD) (Scheen, 2020). This evidence concerns the gene SLC5A2 and chronic kidney disease.